Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.5%

1 terminated out of 22 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed with results

Key Signals

88% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (7)
P 1 (6)
P 2 (1)
P 3 (1)

Trial Status

Recruiting7
Completed7
Not Yet Recruiting3
Unknown2
Terminated1
Withdrawn1

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT05553899Not ApplicableRecruitingPrimary

Utility of PET-MRI in Surveillance of Paediatric Brain Tumours

NCT07558473Not ApplicableNot Yet RecruitingPrimary

Measuring Brain Changes Following Cognitive Intervention in Pediatric Patients With Brain Tumors

NCT06905587Phase 3RecruitingPrimary

Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue

NCT04670016Completed

HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers

NCT06599879Not ApplicableRecruitingPrimary

Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

NCT07390539Phase 1Not Yet Recruiting

B7-H3.CD28Z.CART in CNS Neoplasms

NCT03361033CompletedPrimary

Components of Social Functioning in Survivors of Pediatric Brain Tumors

NCT07338526Not ApplicableRecruitingPrimary

Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT)

NCT04738162Phase 2CompletedPrimary

Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors

NCT03086421Active Not Recruiting

Social Emotional Development in Young Children With Cancer

NCT06309251Recruiting

Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients

NCT05169944Phase 1Completed

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

NCT04023669Phase 1Completed

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

NCT05298995Phase 1RecruitingPrimary

GD2-CAR T Cells for Pediatric Brain Tumours

NCT04525014Phase 1Terminated

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

NCT03936465Phase 1Completed

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

NCT04019470WithdrawnPrimary

Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors

NCT06093165Not ApplicableNot Yet Recruiting

RE-irradiation of Diffuse MIdline Glioma paTients

NCT04722237Not ApplicableUnknown

Acceptance and Commitment Therapy for Neuro-Oncology Wellbeing

NCT05709522UnknownPrimary

Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients

Scroll to load more

Research Network

Activity Timeline